PPARG and fatty liver disease: The fact that we did not observe hepatic steatosis in SDNme7−/− rats (Figure S7) could be explained by opposing actions of decreased Nrep favoring lipid deposition and downregulation of Socs2 and Pparg, both of which were shown to prevent hepatic steatosis in spite of negatively affecting insulin resistance [28,29].